RecruitingNCT05430971

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Sponsor

Immune Oncology Research Institute

Enrollment

200 participants

Start Date

Jul 1, 2022

Study Type

OBSERVATIONAL

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Summary

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.

Eligibility

Inclusion Criteria2

Diagnosis of BPDCN
Signed informed consent form for prospective patients

Exclusion Criteria1

Locations(20)

Sylvester Comprehensive Cancer Center, University of Miami

Miami, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Seattle Children's Cancer and Blood Disorders Center

Seattle, Washington, United States

Hematology Center named after prof. R. Yeolyan

Yerevan, Armenia

University of Calgary

Calgary, Alberta, Canada

Children's Hospital of Eastern Ontario, University of Ottawa

Ottawa, Ontario, Canada

Cyprus Society of Haematology

Nicosia, Cyprus

Oncology Center, Mansoura University Faculty of Medicine

Al Mansurah, Egypt

M. Iashvili Children's Central Hospital

Tbilisi, Georgia

Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical Sciences

New Delhi, India

Pediatric Hematology Oncology, Children's Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad

Baghdad, Iraq

University of Perugia - Azienda Ospedaliera Perugia

Perugia, Italy

Department of Biomedicine and Prevention, University of Rome Tor Vergata

Roma, Italy

Department of hematology, Kuwait Cancer Control Center

Kuwait City, Kuwait

Fundeni Clinical Institute, Department of Acute Leukemia

Bucharest, Romania

China Medical University Children's Hospital

Taichung, Taiwan

Turkish Pediatric Cancer Registry

Ankara, Turkey (Türkiye)

Istanbul University, Oncology Institute

Istanbul, Turkey (Türkiye)

University of Health Sciences, Umraniye Research and Education Hospital, Pediatric Hematology and Oncology Department, Pediatric Bone Marrow Transplantation Unit

Istanbul, Turkey (Türkiye)

Broomfield Hospital, Haematology Mid and South Essex University Hospitals Group

Chelmsford, Essex, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05430971

Related Trials

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

NCT067658761 location

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT060064031 location